We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Nexmed (MM) | NASDAQ:NEXM | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 2.38 | 0 | 01:00:00 |
From Jun 2019 to Jun 2024
The full report is available at: www.microstockprofit.com/ads/NEXM
NexMed Inc. (NEXM) is a pharmaceutical and medical technology company with a focus on developing and commercializing therapeutic products based on its delivery systems. The Company focuses its efforts on new and topical pharmaceutical products based on a penetration enhancement drug delivery technology known as NexACT, which may enable an active drug to be better absorbed through the skin. The NexACT transdermal drug delivery technology is designed to enhance the absorption of an active drug through the skin, overcoming the skin's natural barrier properties, and enabling high concentrations of the active drug to rapidly penetrate the desired site of the skin or extremity.
Message Board Search for NEXM: http://www.boardcentral.com/boards/NEXM
In the report, the analyst notes:
"NEXM, a specialty CRO with a pipeline of products based on the NexACT® technology, recently announced that the Canadian Patent Office has issued a Notice of Allowance for NEXM's patent application entitled, 'Crystalline Salts of Dodecyl 2-(N,N-Dimethylamino)-Propionate.'
"NEXM recently announced that results from a pre-clinical study showed significant improvement in the delivery and half life of A6, a proprietary peptide treatment for ovarian cancer currently in phase 2 development by Angstrom Pharmaceuticals. Specifically, the incorporation of NexACT® enabled the dose of A6 to be cut by half, or from twice per day to once per day delivered subcutaneously, while achieving the same level of efficacy in the mouse lung metastasis model."
To read the entire report visit: www.microstockprofit.com/ads/NEXM
See what investors are saying about NEXM at penny stock forum
MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.
CONTACT: MicroStockProfit.comBrian Johnson
1-888-307-2850
info@microstockprofit.com
1 Year Nexmed (MM) Chart |
1 Month Nexmed (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
